Today’s news includes information on:
- The use of markers for prognosis following first-line treatment for localized prostate cancer
- Results of a Phase II trial of neoadjuvant docetaxel + gefitinib prior to radical prostatectomy
- Results of a Phase III trial of gabapentin in management of ADT-related “hot flashes”
- MRI-directed HIFU in the treatment of localized prostate cancer … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: docetaxel, doubling time, gabapentin, gefitinib, HIFU, hot flashes, PSA velocity | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 